# Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Study · id `cardio:ct-nct01788358` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01788358](<https://clinicaltrials.gov/study/NCT01788358>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01788358

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 508 participants.

## Technical summary

Registry record NCT01788358. Allocation not applicable; no masking; primary purpose treatment. Start 2013-02-14 (actual); primary completion 2014-05-01 (actual). Results posted on 2015-08-17.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 508 participants (enrolled count; ClinicalTrials.gov record NCT01788358, source copy `cardio:ctgov-nct01788358-2017-10-24`, retrieved 2026-10-26)
- Started: 2013-02-14 (actual) (ClinicalTrials.gov record NCT01788358, source copy `cardio:ctgov-nct01788358-2017-10-24`, retrieved 2026-10-26)
- Primary completion: 2014-05-01 (actual) (ClinicalTrials.gov record NCT01788358, source copy `cardio:ctgov-nct01788358-2017-10-24`, retrieved 2026-10-26)
- Completion: 2014-05-01 (actual) (ClinicalTrials.gov record NCT01788358, source copy `cardio:ctgov-nct01788358-2017-10-24`, retrieved 2026-10-26)
- Results first posted: 2015-08-17 (ClinicalTrials.gov record NCT01788358, source copy `cardio:ctgov-nct01788358-2017-10-24`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; Germany; Poland; United Kingdom (ClinicalTrials.gov record NCT01788358, source copy `cardio:ctgov-nct01788358-2017-10-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01788358-2017-10-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension
- Condition: Hypertension
- Intervention (Drug): Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- Intervention (Drug): Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- Intervention (Drug): Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- Intervention (Drug): Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: c74a615e4a99203a520eb7161962e431b363fe4be907b429fbdedb328871e829
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
